ResMed Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.34B | $2.07B | $1.84B | $1.68B | $1.55B | $1.51B | $1.37B | $1.24B |
| Cost of Revenue | $1.01B | $865.0M | $772.2M | $667.5M | $565.2M | $573.8M | $547.8M | $501.8M |
| Gross Profit | $1.33B | $1.20B | $1.07B | $1.01B | $989.8M | $940.7M | $820.7M | $741.3M |
| Gross Margin | 57.0% | 58.1% | 58.0% | 60.2% | 63.7% | 62.1% | 60.0% | 59.6% |
| Operating Expenses | ||||||||
| Research & Development | $155.1M | $144.5M | $118.7M | $114.9M | $118.2M | $120.1M | $109.7M | $92.0M |
| SG&A Expense | $600.4M | $554.0M | $488.1M | $478.6M | $450.4M | $430.8M | $402.6M | $372.2M |
| Operating Income | $541.8M | $425.8M | $429.0M | $409.2M | $405.1M | $354.8M | $294.4M | $266.9M |
| Operating Margin | 23.2% | 20.6% | 23.3% | 24.4% | 26.1% | 23.4% | 21.5% | 21.5% |
| Interest Expense | $28.4M | $28.2M | $11.2M | $5.8M | $6.1M | $6.4M | $4.8M | $1.8M |
| Pretax Income | $521.3M | $418.7M | $439.6M | $435.9M | $431.1M | $385.1M | $331.9M | $303.7M |
| Income Tax Expense | $205.7M | $76.5M | $87.2M | $83.0M | $85.8M | $78.0M | $77.1M | $76.7M |
| Net Income | $315.6M | $342.3M | $352.4M | $352.9M | $345.3M | $307.1M | $254.9M | $227.0M |
| Net Margin | 13.5% | 16.6% | 19.2% | 21.0% | 22.2% | 20.3% | 18.6% | 18.3% |
| EPS (Basic) | $2.21 | $2.42 | $2.51 | $2.51 | $2.44 | $2.15 | $1.75 | $1.49 |
| EPS (Diluted) | $2.19 | $2.40 | $2.49 | $2.47 | $2.39 | $2.10 | $1.71 | $1.44 |
| Shares Outstanding (Basic) | 142.8M | 141.4M | 140.2M | 140.5M | 141.5M | 143.0M | 145.9M | 152.5M |
| Shares Outstanding (Diluted) | 144.0M | 142.5M | 141.7M | 142.7M | 144.4M | 146.4M | 149.3M | 157.2M |
| Dividends Per Share | $1.40 | $1.32 | $1.20 | $1.12 | $1.00 | $0.68 | — | — |